Single Patient Protocol for an NRG1 Fusion Positive Metastatic Pancreatic Cancer Patient Using Seribantumab

• Status: Not yet recruiting
• Trial end date: 2022-03-21
• Target enrollment: 0
• Participant gender: Female

Summary

NRG1 gene fusions are extremely rare across solid tumours (estimate 0.3-0.5%). However, it is felt to be an actionable and potentially major growth pathway for those tumours that harbour this gene rearrangement. Tumours that harbour NRG1 fusions are driven by HER3 overactivation. Seribantumab is a mono-clonal antibody against HER3, it binds HER3 and inhibits NRG1-dependent activation and HER2 dimerization.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ottawa Hospital Research Institute

Criteria

Inclusion Criteria:

• Serious, life-threatening condition

• Not eligible for, or exhausted all other treatment options or causing significant toxicity

• No other way to access treatment

Exclusion Criteria:

-